# N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer

> **NCT01138137** · PHASE1 · WITHDRAWN · sponsor: **OHSU Knight Cancer Institute**

## Conditions studied

- Ovarian Carcinoma, Stage 3 or 4
- Epithelial Ovarian Carcinoma
- Primary Peritoneal Carcinoma

## Interventions

- **DRUG:** Paclitaxel
- **DRUG:** N-acetylcysteine
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT01138137
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2010-06
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No funding was available for the cost of the IV N-acetylcysteine (NAC).
- **Last updated:** 2017-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01138137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01138137, "N-acetylcysteine Given IV With Cisplatin and Paclitaxel in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01138137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*